Trademark: KRONEXTA 1437797
Word
KRONEXTA
ID
1437797
Trademark Type
Word
Status
Removed
Not renewed: Renewal fee not paid
Not renewed: Renewal fee not paid
Application Date
19 July 2011
Registration Date
19 July 2011
Owner(s)
Service
Spruson & Ferguson
Goods and Services:
Class 5:
Pharmaceutical and veterinary preparations, preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of age-related diseases, pharmaceutical preparation used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparation used for the treatment for benign prostatic hyperplasia (BPH), pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform, pharmaceutical preparations based on angiogenesis inhibitors platform, pharmaceutical preparations used to induce apoptosis
Pharmaceutical and veterinary preparations, preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of age-related diseases, pharmaceutical preparation used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparation used for the treatment for benign prostatic hyperplasia (BPH), pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform, pharmaceutical preparations based on angiogenesis inhibitors platform, pharmaceutical preparations used to induce apoptosis